Links between mTOR and the immunoproteasome: Therapeutic targets for cardiac hypertrophy?

Journal of Molecular and Cellular Cardiology

Volumn 89, Issue , 2015, Pages 113-115

  Ackermann, Maegen A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOPROTEASOME; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; PROTEIN KINASE B; STAT3 PROTEIN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; AUTOPHAGY; CARDIOMYOPATHY; CELL POLARITY; CELL PROLIFERATION; CELL SURVIVAL; EDITORIAL; ENZYME INHIBITION; HEART MUSCLE INJURY; HEART VENTRICLE HYPERTROPHY; MUSCLE DEVELOPMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; CARDIOMEGALY; DRUG EFFECTS; GENETICS; HUMAN;

ANIMALS; CARDIOMEGALY; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84952720641     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.09.014     Document Type: Editorial

References (64)

1. Zhang H.M., Fu J., Hamilton R., Diaz V., Zhang Y. The mammalian target of rapamycin modulates the immunoproteasome system in the heart. J. Mol. Cell. Cardiol. 2015, 86:158-167.
2. Sciarretta S., Volpe M., Sadoshima J. Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ. Res. 2014, 114:549-564.
3. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369:756-758.
4. Sabatini D.M., Pierchala B.A., Barrow R.K., Schell M.J., Snyder S.H. The rapamycin and FKBP12 target (RAFT) displays phosphatidylinositol 4-kinase activity. J Biol Chem. 1995, 270:20875-20878.
5. Sabers C.J., Martin M.M., Brunn G.J., Williams J.M., Dumont F.J., Wiederrecht G., et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 1995, 270:815-822.
6. Johnson S.C., Rabinovitch P.S., Kaeberlein M. MTOR is a key modulator of ageing and age-related disease. Nature 2013, 493:338-345.
7. Kapahi P., Chen D., Rogers A.N., Katewa S.D., Li P.W., Thomas E.L., et al. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab. 2010, 11:453-465.
8. Laplante M., Sabatini D.M. MTOR signaling in growth control and disease. Cell 2012, 149:274-293.
9. Laplante M., Sabatini D.M. Regulation of mTORC1 and its impact on gene expression at a glance. J. Cell Sci. 2013, 126:1713-1719.
10. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
11. Shende P., Plaisance I., Morandi C., Pellieux C., Berthonneche C., Zorzato F., et al. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation 2011, 123:1073-1082.
12. Tamai T., Yamaguchi O., Hikoso S., Takeda T., Taneike M., Oka T., et al. Rheb (Ras homologue enriched in brain)-dependent mammalian target of rapamycin complex 1 (mTORC1) activation becomes indispensable for cardiac hypertrophic growth after early postnatal period. J Biol Chem. 2013, 288:10176-10187.
13. Zhang D., Contu R., Latronico M.V., Zhang J., Rizzi R., Catalucci D., et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J. Clin. Invest. 2010, 120:2805-2816.
14. Zhu Y., Pires K.M., Whitehead K.J., Olsen C.D., Wayment B., Zhang Y.C., et al. Mechanistic target of rapamycin (mtor) is essential for murine embryonic heart development and growth. PLoS ONE 2013, 8.
15. Flynn J.M., O'Leary M.N., Zambataro C.A., Academia E.C., Presley M.P., Garrett B.J., et al. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell. 2013, 12:851-862.
16. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
17. Wu J.J., Liu J., Chen E.B., Wang J.J., Cao L., Narayan N., et al. Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. Cell Rep. 2013, 4:913-920.
18. Aoyama T., Matsui T., Novikov M., Park J., Hemmings B., Rosenzweig A. Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response. Circulation 2005, 111:1652-1659.
19. Choi J.C., Wu W., Muchir A., Iwata S., Homma S., Worman H.J. Dual specificity phosphatase 4 mediates cardiomyopathy caused by lamin a/C (LMNA) gene mutation. J Biol Chem. 2012, 287:40513-40524.
20. Marin T.M., Keith K., Davies B., Conner D.A., Guha P., Kalaitzidis D., et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J. Clin. Invest. 2011, 121:1026-1043.
21. McMullen J.R., Sherwood M.C., Tarnavski O., Zhang L., Dorfman A.L., Shioi T., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004, 109:3050-3055.
22. Ramos FJ, Chen SC, Garelick MG, Dai DF, Liao CY, Schreiber KH, et al. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med. 2012;4:144ra03.
23. Shioi T., McMullen J.R., Tarnavski O., Converso K., Sherwood M.C., Manning W.J., et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003, 107:1664-1670.
24. Volkers M., Toko H., Doroudgar S., Din S., Quijada P., Joyo A.Y., et al. Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:12661-12666.
25. Wu X., Cao Y., Nie J., Liu H., Lu S., Hu X., et al. Genetic and pharmacological inhibition of Rheb1-mTORC1 signaling exerts cardioprotection against adverse cardiac remodeling in mice. Am J Pathol. 2013, 182:2005-2014.
26. Buss S.J., Muenz S., Riffel J.H., Malekar P., Hagenmueller M., Weiss C.S., et al. Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J. Am. Coll. Cardiol. 2009, 54:2435-2446.
27. Sciarretta S., Zhai P., Shao D., Maejima Y., Robbins J., Volpe M., et al. Rheb is a critical regulator of autophagy during myocardial ischemia: pathophysiological implications in obesity and metabolic syndrome. Circulation 2012, 125:1134-1146.
28. Zhai P., Sciarretta S., Galeotti J., Volpe M., Sadoshima J. Differential roles of GSK-3beta during myocardial ischemia and ischemia/reperfusion. Circ. Res. 2011, 109:502-511.
29. Shen W.H., Chen Z., Shi S., Chen H., Zhu W., Penner A., et al. Cardiac restricted overexpression of kinase-dead mammalian target of rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function. J Biol Chem. 2008, 283:13842-13849.
30. Song X., Kusakari Y., Xiao C.Y., Kinsella S.D., Rosenberg M.A., Scherrer-Crosbie M., et al. MTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. Am J Physiol Cell Physiol. 2010, 299:C1256-C1266.
31. Shiojima I., Sato K., Izumiya Y., Schiekofer S., Ito M., Liao R., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 2005, 115:2108-2118.
32. Zolk O., Schenke C., Sarikas A. The ubiquitin-proteasome system: focus on the heart. Cardiovasc. Res. 2006, 70:410-421.
33. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426:895-899.
34. Aki M., Shimbara N., Takashina M., Akiyama K., Kagawa S., Tamura T., et al. Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J. Biochem. 1994, 115:257-269.
35. Leithe E., Rivedal E. Ubiquitination and down-regulation of gap junction protein connexin-43 in response to 12-O-tetradecanoylphorbol 13-acetate treatment. J Biol Chem. 2004, 279:50089-50096.
36. Leithe E., Rivedal E. Epidermal growth factor regulates ubiquitination, internalization and proteasome-dependent degradation of connexin43. J. Cell Sci. 2004, 117:1211-1220.
37. Shenoy S.K., McDonald P.H., Kohout T.A., Lefkowitz R.J. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 2001, 294:1307-1313.
38. Herrmann J., Ciechanover A., Lerman L.O., Lerman A. The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc. Res. 2004, 61:11-21.
39. Walowitz J.L., Bradley M.E., Chen S., Lee T. Proteolytic regulation of the zinc finger transcription factor YY1, a repressor of muscle-restricted gene expression. J Biol Chem. 1998, 273:6656-6661.
40. Mearini G., Schlossarek S., Willis M.S., Carrier L. The ubiquitin-proteasome system in cardiac dysfunction. Biochim. Biophys. Acta 1782, 2008:749-763.
41. Portbury A.L., Ronnebaum S.M., Zungu M., Patterson C., Willis M.S. Back to your heart: ubiquitin proteasome system-regulated signal transduction. J. Mol. Cell. Cardiol. 2012, 52:526-537.
42. Willis M.S., Patterson C. Into the heart: the emerging role of the ubiquitin-proteasome system. J. Mol. Cell. Cardiol. 2006, 41:567-579.
43. Balasubramanian S., Mani S., Shiraishi H., Johnston R.K., Yamane K., Willey C.D., et al. Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium is accompanied by changes in specific E3 ligases. J. Mol. Cell. Cardiol. 2006, 41:669-679.
44. Tsukamoto O., Minamino T., Okada K., Shintani Y., Takashima S., Kato H., et al. Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem. Biophys. Res. Commun. 2006, 340:1125-1133.
45. Depre C., Wang Q., Yan L., Hedhli N., Peter P., Chen L., et al. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 2006, 114:1821-1828.
46. Razeghi P, Baskin KK, Sharma S, Young ME, Stepkowski S, Essop MF, et al. Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart. Biochem. Biophys. Res. Commun. 2006;342:361-4.
47. Arya R., Kedar V., Hwang J.R., McDonough H., Li H.H., Taylor J., et al. Muscle ring finger protein-1 inhibits PKC(epsilon) activation and prevents cardiomyocyte hypertrophy. J. Cell Biol. 2004, 167:1147-1159.
48. Fielitz J., Kim M.S., Shelton J.M., Latif S., Spencer J.A., Glass D.J., et al. Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J. Clin. Invest. 2007, 117:2486-2495.
49. Fielitz J., van Rooij E., Spencer J.A., Shelton J.M., Latif S., van der Nagel R., et al. Loss of muscle-specific RING-finger 3 predisposes the heart to cardiac rupture after myocardial infarction. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4377-4382.
50. Li H.H., Kedar V., Zhang C., McDonough H., Arya R., Wang D.Z., et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J. Clin. Invest. 2004, 114:1058-1071.
51. Li H.H., Willis M.S., Lockyer P., Miller N., McDonough H., Glass D.J., et al. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of forkhead proteins. J. Clin. Invest. 2007, 117:3211-3223.
52. Toth A., Nickson P., Qin L.L., Erhardt P. Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase. J Biol Chem. 2006, 281:3679-3689.
53. Willis M.S., Ike C., Li L., Wang D.Z., Glass D.J., Patterson C. Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ. Res. 2007, 100:456-459.
54. Witt C.C., Witt S.H., Lerche S., Labeit D., Back W., Labeit S. Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2. EMBO J. 2008, 27:350-360.
55. Cai Z.P., Shen Z., Van Kaer L., Becker L.C. Ischemic preconditioning-induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency. FASEB J. 2008, 22:4248-4257.
56. Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773-785.
57. Purcell N.H., Tang G., Yu C., Mercurio F., DiDonato J.A., Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6668-6673.
58. Dan H.C., Cooper M.J., Cogswell P.C., Duncan J.A., Ting J.P., Baldwin A.S. Akt-dependent regulation of NF-(kappa)B is controlled by mTOR and raptor in association with IKK. Genes Dev. 2008, 22:1490-1500.
59. Razeghi P., Sharma S., Ying J., Li Y.P., Stepkowski S., Reid M.B., et al. Atrophic remodeling of the heart in vivo simultaneously activates pathways of protein synthesis and degradation. Circulation 2003, 108:2536-2541.
60. Zhang Y., Nicholatos J., Dreier J.R., Ricoult S.J., Widenmaier S.B., Hotamisligil G.S., et al. Coordinated regulation of protein synthesis and degradation by mTORC1. Nature 2014, 513:440-443.
61. Giordano A., Avellino R., Ferraro P., Romano S., Corcione N., Romano M.F. Rapamycin antagonizes NF-kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth muscle cells and enhances apoptosis. Am J Physiol Heart Circ Physiol. 2006, 290:H2459-H2465.
62. Jundt F., Raetzel N., Muller C., Calkhoven C.F., Kley K., Mathas S., et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein (beta) and NF-(kappa)B activity in hodgkin and anaplastic large cell lymphomas. Blood 2005, 106:1801-1807.
63. Chen X, Zeng S, Zou J, Chen Y, Yue Z, Gao Y, et al. Rapamycin attenuated cardiac hypertrophy induced by isoproterenol and maintained energy homeostasis via inhibiting NF-kappaB activation. Mediat. Inflamm. 2014;2014:868753.
64. Gao X.M., Wong G., Wang B., Kiriazis H., Moore X.L., Su Y.D., et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J. Hypertens. 2006, 24:1663-1670.